Login
$QURE
$21.83 -$0.05 (0.23%) After hours

$QURE SEC Filings

Filed On Filing
10 Nov 2026 Form 4: Meek David D., Director

Sold 9,080 shares ($193K)

06 Nov 2026 144
04 Nov 2026 10-Q
04 Nov 2026 8-K: Results of Operations and Financial Condition

~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease; PDUFA target action date of May 1, 2027 ~

03 Nov 2026 Form 4: Abi-Saab Walid, Chief Medical Officer

Received 18,750 shares as a grant or award

02 Nov 2026 8-K: Regulation FD Disclosure; Other Events

uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease

16 Oct 2026 SCHEDULE 13G/A
29 Sep 2026 8-K: Regulation FD Disclosure

Ashley – Huntington’s Disease Community Advocate Phase I/II ifezuntirgene inilparvovec (AMT-130) Huntington’s Disease Program Update September 29, 2026

02 Sep 2026 8-K: Regulation FD Disclosure

uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease

14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G
29 Jul 2026 S-8
29 Jul 2026 10-Q
29 Jul 2026 8-K: Results of Operations and Financial Condition

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~

20 Jul 2026 SCHEDULE 13G/A
16 Jul 2026 SCHEDULE 13G
07 Jul 2026 Form 4: Kapusta Matthew C, Director

Received 21,082 shares by exercise or conversion ($409K) · Sold 21,082 shares ($952K)

02 Jul 2026 Form 4: Abi-Saab Walid, Chief Medical Officer

Received 10,000 shares by exercise or conversion ($55.9K) · Sold 30,000 shares ($1.39M)

02 Jul 2026 Form 4: Kaye Jack, Director

Received 21,167 shares by exercise or conversion ($496K) · Sold 21,167 shares ($983K)

02 Jul 2026 144

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support